Hommos Musab S, El-Zoghby Ziad M
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Transplant Direct. 2017 Jul 11;3(8):e193. doi: 10.1097/TXD.0000000000000708. eCollection 2017 Aug.
End-stage liver disease (ESLD) is the most common cause of secondary immunoglobulin A nephropathy (IgAN). Multiple mechanisms have been proposed to explain the association between liver disease and IgAN. Although some mechanisms are expected to reverse in patients after liver transplant, the long-term renal prognosis is unclear for these patients.
This observational retrospective cohort study examined the renal outcomes of 14 patients who had IgAN with end-stage liver disease and subsequently underwent either liver transplant alone or combined liver and kidney transplant at a single tertiary care center.
Of the 7 patients who underwent liver transplant alone, hematuria persisted in 2, 4 had progressive loss of kidney function with worsening proteinuria in 3 but only 1 reached end-stage renal disease 5 years posttransplant. Among 7 combined liver and kidney transplant recipients, 1 had histologic and 1 had histologic and clinical recurrence of IgAN without kidney allograft loss.
IgAN in patients with advanced liver disease does not necessarily resolve after liver transplant but has overall favorable renal outcomes.
终末期肝病(ESLD)是继发性免疫球蛋白A肾病(IgAN)最常见的病因。已提出多种机制来解释肝病与IgAN之间的关联。尽管预计一些机制在肝移植患者中会逆转,但这些患者的长期肾脏预后尚不清楚。
这项观察性回顾性队列研究检查了14例患有IgAN合并终末期肝病的患者的肾脏结局,这些患者随后在单一的三级医疗中心接受了单独肝移植或肝肾联合移植。
在仅接受肝移植的7例患者中,2例血尿持续存在,4例肾功能进行性丧失,3例蛋白尿加重,但仅1例在移植后5年达到终末期肾病。在7例肝肾联合移植受者中,1例发生IgAN组织学复发,1例发生IgAN组织学和临床复发,但肾移植未丢失。
晚期肝病患者的IgAN在肝移植后不一定会缓解,但总体肾脏预后良好。